| The Estates At Twin Rivers Llc | |
| 305 Fremont Street, Anoka, Minnesota 55303 | |
| (763) 421-5660 | |
| Name | The Estates At Twin Rivers Llc |
|---|---|
| Location | 305 Fremont Street, Anoka, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 50 |
| Occupancy Rate | 70.2% |
| Medicare ID (CCN) | 245298 |
| Legal Business Name | The Estates At Anoka Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1013455856 |
| Organization Name | THE ESTATES AT ANOKA LLC |
| Doing Business As | THE ESTATE AT TWIN RIVERS |
| Address | 305 Fremont St, Anoka, MN 55303 |
| Phone Number | 763-421-5660 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.
Researchers here have found evidence that combining a drug typically used to treat rheumatoid arthritis with chemotherapy might help reduce fatigue and muscle wasting that often afflicts cancer patients.
Like a spotlight that illuminates an otherwise dark scene, attention brings to mind specific details of our environment while shutting others out. A new study by researchers at the Salk Institute for Biological Studies shows that the superior colliculus, a brain structure that primarily had been known for its role in the control of eye and head movements, is crucial for moving the mind's spotlight.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.
Side effects are a major reason that drugs are taken off the market and a major reason why patients stop taking their medications, but scientists are now reporting the development of a new way to predict those adverse reactions ahead of time.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.
Researchers here have found evidence that combining a drug typically used to treat rheumatoid arthritis with chemotherapy might help reduce fatigue and muscle wasting that often afflicts cancer patients.
Like a spotlight that illuminates an otherwise dark scene, attention brings to mind specific details of our environment while shutting others out. A new study by researchers at the Salk Institute for Biological Studies shows that the superior colliculus, a brain structure that primarily had been known for its role in the control of eye and head movements, is crucial for moving the mind's spotlight.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.
Side effects are a major reason that drugs are taken off the market and a major reason why patients stop taking their medications, but scientists are now reporting the development of a new way to predict those adverse reactions ahead of time.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.48 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.92 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 37.74 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 10.8 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.61 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.79 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.17 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 23.42 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 73.13 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.57 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 18.31 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20.54 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 12.79 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.58 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 79.48 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 79.73 | 82.93 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.
Researchers here have found evidence that combining a drug typically used to treat rheumatoid arthritis with chemotherapy might help reduce fatigue and muscle wasting that often afflicts cancer patients.
Like a spotlight that illuminates an otherwise dark scene, attention brings to mind specific details of our environment while shutting others out. A new study by researchers at the Salk Institute for Biological Studies shows that the superior colliculus, a brain structure that primarily had been known for its role in the control of eye and head movements, is crucial for moving the mind's spotlight.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.
Side effects are a major reason that drugs are taken off the market and a major reason why patients stop taking their medications, but scientists are now reporting the development of a new way to predict those adverse reactions ahead of time.
› Verified 7 days ago
Anoka Rehabilitation And Living Center Location: 3000 4th Avenue, Anoka, Minnesota 55303 Phone: (763) 528-6400 | |
The Estates At Twin Rivers Llc Location: 305 Fremont Street, Anoka, Minnesota 55303 Phone: (763) 421-5660 |